Form 4: CVRx Director Kevin J. Ballinger Reports Stock Option Grant

Director Kevin J. Ballinger reported the acquisition of stock options in CVRx, Inc. on September 3, 2024.

Summary

• On September 3, 2024, Kevin J. Ballinger, a director of CVRx, Inc., reported the acquisition of stock options.
• The stock option grants him the right to buy 36,136 shares of CVRx common stock at an exercise price of $9.05.
• The options vest in three equal annual installments starting on the first anniversary of the grant date.
• The options expire on September 2, 2034.
• Following the transaction, Ballinger directly owns 36,136 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like medical technology.
• The vesting schedule of one-third annually over three years is a standard vesting arrangement.
• The exercise price is set at the market price on the grant date.

Stakeholder Impact

• The stock option grant could incentivize the director to work towards increasing shareholder value.

Key Dates